Patents by Inventor Patrick James Sarver

Patrick James Sarver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2
    Publication number: 20220089597
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: March 3, 2021
    Publication date: March 24, 2022
    Inventors: Jeffrey T. Bagdanoff, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Mitsunori Kato, Matthew J. LaMarche, Patrick James Sarver, Michael Shultz, Troy Douglas Smith, Sarah Williams
  • COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2
    Publication number: 20210309663
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: March 3, 2021
    Publication date: October 7, 2021
    Inventors: Jeffrey T. Bagdanoff, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Mitsunori Kato, Matthew J. LaMarche, Patrick James Sarver, Michael Shultz, Troy Douglas Smith, Sarah Williams
  • Compounds and compositions for inhibiting the activity of SHP2
    Patent number: 10975080
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: April 13, 2021
    Assignee: NOVARTIS AG
    Inventors: Jeffrey T. Bagdanoff, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Mitsunori Kato, Matthew J. LaMarche, Patrick James Sarver, Michael Shultz, Troy Douglas Smith, Sarah Williams
  • Tricyclic compounds and compositions as kinase inhibitors
    Patent number: 10377770
    Abstract: The present invention provides compounds of Formula (A): (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent, and methods of using the compositions and combinations to treat conditions including cancers.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: August 13, 2019
    Assignee: Novartis AG
    Inventors: Robert John Aversa, Matthew T. Burger, Michael Patrick Dillon, Thomas A. Dineen, Jr., Rajesh Karki, Savithri Ramurthy, Vivek Rauniyar, Richard Robinson, Patrick James Sarver
  • COMPOUNDS AND COMPOSITIONS FOR INHBITING THE ACTIVITY OF SHP2
    Publication number: 20190185475
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, Y4 R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: June 15, 2016
    Publication date: June 20, 2019
    Inventors: Jeffrey T. Bagdanoff, Zhuoliang Chen, Michael Dore, Jorge Garcia Fortanet, Mitsunori Kato, Matthew J. LaMarche, Patrick James Sarver, Michael Shultz, Troy Douglas Smith, Sarah Williams
  • Compounds and compositions for inhibiting the activity of SHP2
    Patent number: 10287266
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2, R4a, R4b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: May 14, 2019
    Assignee: Novartis AG
    Inventors: Zhuoliang Chen, Jorge Garcia Fortanet, Andriana Jouk, Rajesh Karki, Matthew J. LaMarche, Gang Liu, Mark G. Palermo, Lawrence Blas Perez, Patrick James Sarver, Michael David Shultz, Martin Sendzik, Bakary-Barry Toure, Bing Yu
  • TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
    Publication number: 20180362542
    Abstract: The present invention provides compounds of Formula (A): (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent, and methods of using the compositions and combinations to treat conditions including cancers.
    Type: Application
    Filed: December 14, 2016
    Publication date: December 20, 2018
    Inventors: Robert John AVERSA, Matthew T. BURGER, Michael Patrick DILLON, Thomas A. DINEEN, Jr., Rajesh KARKI, Savrithi RAMURTHY, Vivek RAUNIYAR, Richard ROBINSON, Patrick James SARVER
  • COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2
    Publication number: 20180186770
    Abstract: The present invention relates to compounds of formula I: in which Y1, Y2, Y3, R1, R2, R4a, R5b, R5a, R5b, R6a and R6b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Application
    Filed: June 15, 2016
    Publication date: July 5, 2018
    Inventors: Zhuoliang Chen, Jorge Garcia Fortanet, Andriana Jouk, Rajesh Karki, Matthew J. LaMarche, Gang Liu, Mark G. Palermo, Lawrence Blas Perez, Patrick James Sarver, Michael David Shultz, Martin Sendzik, Bakary-Barry Toure, Bing Yu